Does heart failure exacerbation increase response to warfarin? A critical review of the literature

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2089-2094

  Self, Timothy H ^a   Reaves, Anne B ^a   Oliphant, Carrie S ^a   Sands, Chris ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Decompensated heart failure; Heart failure; Warfarin effect

Indexed keywords

ANTICOAGULANT AGENT; CHLORTALIDONE; DICOUMAROL; DIURETIC AGENT; SPIRONOLACTONE; WARFARIN;

ADULT; AGED; BLEEDING; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG ANTAGONISM; HEART FAILURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PROTHROMBIN TIME; REVIEW; TREATMENT RESPONSE;

ANTICOAGULANTS; HEART FAILURE, CONGESTIVE; HUMANS; INTERNATIONAL NORMALIZED RATIO; WARFARIN;

EID: 33751200623     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132479     Document Type: Review

References (26)

1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. Chest 2004;126:204S-33
2. Wells PS, Holbrook AN, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83
3. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004;75:204-12
4. Loebstein R, Yonath H, Peleg D, et al. Intel-individual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 2001;70:159-64
5. Demirkan K, Stephens MA, Newman KP, Self TH. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000;93:448-54
6. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400
7. Lee VWY, You JHS, Lee KKC, et al. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis 2005;20:33-8
8. Heart disease and stroke statistics 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:85-151
9. Cotlove E, Vorzimer JJ. Serial prothrombin estimations in cardiac patients: diagnostic and therapeutic implications; use of dicumarol. Ann Intern Med 1946;24:648-65
10. Wishart JH, Chapman CB. Dicoumarol therapy in congestive heart failure. N Engl J Med 1948;239:701-4
11. Anderson GM, Hull E. The use of Dicumarol as an adjunct to the treatment of congestive heart failure. South Med J 1948;41:365-71
12. Stats D, Davison S. The increased hypoprothrombinemic effect of small dose of dicoumarol in congestive heart failure. Am J Med Sci 1949;218:318-23
13. Reisner EH, Norman J, Field W, et al. The effect of liver dysfunction on the response to dicoumarol. Am J Med Sci 1949;217:445-7
14. Killip T, Payne M. High serum transaminase activity in heart disease. Circulation 1960;21:646-60
15. Peyman MA. The significance of hemorrhage during the treatment of patients with coumarin anticoagulants. Acta Med Scand 1958;162(Suppl 338):1-62
16. Petitti DB, Storm BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989;42:759-64
17. Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international survey. Br J Haematol 1982;51:479-85
18. Doecke CJ, Cosh DG, Gallus AS. Standardized initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomized trial and risk factors for an excessive warfarin response. Aust NZ J Med 1991;21:319-24
19. Oates A, Jackson PR, Austin CA, et al. A new regimen for starting warfarin therapy in outpatients. Br J Clin Pharmacol 1998;46:157-61
20. Brigden ML, Kay C, Le A, et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an outpatient population. Am J Hematol 1998;59:22-7
21. Le Counteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359-73
22. Franco V, Polanczyk CA, Clausell N, et al. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 2004;116:651-6
23. Carr JG, Stevenson LW, Walden JA, et al. Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63:709-13
24. Anker SD, Ponikowski P. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-3
25. O'Reilly RA, Sahud MA, Aggeler PM. Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs on man. Ann NY Acad Sci 1971;179:173-86
26. O'Reilly RA. Interaction of spironolactone and racemic warfarin in man. Clin Pharmacol Ther 1980;27:198-201